research Managing Adverse Events Associated with Vismodegib in the Treatment of Basal Cell Carcinoma
Adverse events from vismodegib can be managed effectively to ensure optimal treatment.
Search
for
Sort by
Research
30 / 76 results
research A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma
Sonidegib and vismodegib are similarly effective for advanced basal cell carcinoma, but sonidegib might have a slightly better safety profile.
research Smoothened Receptor Inhibitor Vismodegib for the Treatment of Basal Cell Carcinoma: A Retrospective Analysis of Efficacy and Side Effects
Vismodegib is effective for basal cell carcinoma but has severe side effects.
research A Slow-Cycling LGR5 Tumor Population Mediates Basal Cell Carcinoma Relapse After Therapy
A small group of slow-growing cells causes basal cell carcinoma to return after treatment.
research Targeting Smoothened for Therapeutic Gain
Targeting the Smoothened receptor shows promise for treating certain cancers.
research Cutaneous Reactions to Chemotherapeutic Drugs and Targeted Therapy for Cancer
Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.
research Alopecia in Patients Treated with Molecularly Targeted Anticancer Therapies
Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.
research Emerging Drugs and Combination Strategies for Basal Cell Carcinoma
New treatments for a type of skin cancer show promise but have side effects and may work better with other therapies.
research From Basal Cell Carcinoma Morphogenesis to Alopecia Induced by Hedgehog Inhibitors: Connecting the Dots
The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.
research Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
research Basal Cell Carcinoma, Hedgehog Signaling, and Targeted Therapeutics: The Long and Winding Road
New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.
research Hair Loss and Hedgehog Inhibitors: A Class Effect?
Hedgehog pathway inhibitors used for skin cancer can cause significant hair loss, which may improve after stopping the medication.
research Malignant Epithelial Tumors: Part II. Therapy and Prevention
The document concludes that individualized treatment for malignant epithelial tumors is necessary and more research on metastatic squamous cell carcinoma treatments is needed.
research Scalp Basal Cell Carcinoma: A Different Entity?
Scalp basal cell carcinoma may be more aggressive and harder to treat than other types, requiring special attention and further research.
research Adverse Hair Reactions to New Targeted Therapies for Cancer
New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.
research Cells to Surgery Quiz: December 2017
Mohs micrographic surgery is effective for treating basal cell carcinoma on the eyelid, while radiotherapy has higher recurrence rates, and topical vitamin D3 may reduce and delay BCC formation in mice.
research Alopecia Due to Chemotherapeutics, Hedgehog Inhibitors, Targeted Antibody Therapies, and Immune Checkpoint Inhibitors
Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
research The Hedgehog-GLI1 Pathway Is Important for Fibroproliferative Properties in Keloids and as a Candidate Therapeutic Target
Targeting the HEDGEHOG-GLI1 pathway could help treat keloids.
research Keloid Pathogenesis and Fibroproliferative Properties Are Dependent on Stem Cells Regulated by the Hedgehog-Gli1 Pathway
Blocking the HEDGEHOG-GLI1 pathway can reduce keloid growth and may be a potential treatment.
research Roles of the Hedgehog Signaling Pathway in Cutaneous Physiology and Oncology
The Hedgehog Signaling Pathway is important for skin and hair development and skin cancer treatment, but more research is needed to understand it fully.
research WNT Signaling in Disease
The WNT signaling pathway is important in many diseases and targeting it could offer new treatments.
research Hedgehog Pathway Inhibitors Against Tumor Microenvironment
Hedgehog pathway inhibitors can treat certain aggressive cancers but face limitations like resistance and side effects.
research Prophylaxis and Management of Skin Toxicities
Preventive measures and effective management are crucial for reducing skin side effects in cancer treatment.
research Retrospective Analysis of Smell and Taste Disturbances Associated with Dermatologic Medications Reported to the United States Food and Drug Administration and Relevance to COVID-19 Infections
AGA might indicate higher risk for severe COVID-19.
research Chemotherapy-Induced Hair Loss: The Use of Biomarkers for Predicting Alopecic Severity and Treatment Efficacy
Scalp cooling to prevent hair loss from chemotherapy works for some but not all, and studying hair damage markers could improve prevention and treatment.
research Anti-Basal Cell Carcinoma Efficacy of a Topical Hedgehog Inhibitor Without Adverse Effects in Gorlin Syndrome Patients in a Phase 2 Randomized Controlled Trial
Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
research Management of Alopecia Due to Cancer Therapies
The document concludes that scalp cooling and treatments like minoxidil can help manage hair loss from cancer therapy.
research Cutaneous Adverse Effects of Targeted Therapies
Targeted cancer therapies often cause serious skin problems that need careful management.
research Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors
The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
research Cutaneous Manifestations and Considerations in COVID-19 Pandemic: A Systematic Review
COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.